Differential Cav2.1 and Cav2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABAB receptor activation
about
The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic PotentialTransforming conotoxins into cyclotides: Backbone cyclization of P-superfamily conotoxinsPresynaptic GABAB autoreceptor regulation of nicotinic acetylcholine receptor mediated [(3)H]-GABA release from mouse synaptosomes.Structure-Activity Studies of Cysteine-Rich α-Conotoxins that Inhibit High-Voltage-Activated Calcium Channels via GABA(B) Receptor Activation Reveal a Minimal Functional Motif.Less is More: Design of a Highly Stable Disulfide-Deleted Mutant of Analgesic Cyclic α-Conotoxin Vc1.1.Baclofen mediates neuroprotection on hippocampal CA1 pyramidal cells through the regulation of autophagy under chronic cerebral hypoperfusion.Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.Novel coupling is painlessReview: Cav2.3 R-type Voltage-Gated Ca2+ Channels - Functional Implications in Convulsive and Non-convulsive Seizure Activity.α9-containing nicotinic acetylcholine receptors and the modulation of pain.αO-Conotoxin GeXIVA disulfide bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency and selectivity for the human α9α10 subtype.RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia.α-Conotoxin Vc1.1 inhibits human dorsal root ganglion neuroexcitability and mouse colonic nociception via GABAB receptors.Molecular Engineering of Conus Peptides as Therapeutic Leads.G-Protein Coupled Receptors Targeted by Analgesic Venom Peptides.A novel α-conopeptide Eu1.6 inhibits N-type (CaV2.2) calcium channels and exhibits potent analgesic activity.Cyclic analogues of α-conotoxin Vc1.1 inhibit colonic nociceptors and provide analgesia in a mouse model of chronic abdominal pain.The CaV2α1 EF-hand F helix tyrosine, a highly conserved locus for GPCR inhibition of CaV2 channels.
P2860
Q26781422-C3D4C157-1A35-4953-95D1-03FEBB931818Q27701553-A5C2B725-3F7C-4F35-86DA-E6B16087D102Q34073244-C27D0F42-48B8-4483-83F3-438746965ACFQ35947186-094E54B2-BD04-4170-B438-BAA0666C0148Q35974234-531D0D5F-375D-4533-B1FD-07CCF3BA796EQ36100187-27D9AF14-0270-44A9-A262-8D187B5E5944Q37695948-2D4ABFDB-7147-4BFD-BCDD-CE818E0BAF74Q38579158-1A5263ED-9DD5-4CDA-9CDA-EE74AFAAFCD2Q39008701-2D963B71-2EC0-4577-90CA-928A7D438BAFQ39405111-71A8571E-2A39-4A6D-9D51-45061305DDC5Q39628410-6DDC57C6-4115-4161-9BB9-7E8BF45189F5Q41075047-AFB05B2F-BC1B-4B18-AB09-FD77E95669C7Q41160258-A4C0D5F9-7B69-4254-9173-CC85CE322A0FQ46272595-5739D490-24CD-4CE3-82FB-DD99EB3ACC05Q47104016-1B9167A1-8EB1-4E14-A539-0971214A02DBQ47561709-F35584B1-6E9C-4928-B700-2FFF7912C71CQ48198015-F7F05287-5E4B-40BD-A00C-1F22EA6CD422Q49830370-377AAEB2-5958-4679-B4B8-83B6C1417103
P2860
Differential Cav2.1 and Cav2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABAB receptor activation
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Differential Cav2.1 and Cav2.3 ...... via GABAB receptor activation
@en
Differential Cav2.1 and Cav2.3 ...... via GABAB receptor activation.
@nl
type
label
Differential Cav2.1 and Cav2.3 ...... via GABAB receptor activation
@en
Differential Cav2.1 and Cav2.3 ...... via GABAB receptor activation.
@nl
prefLabel
Differential Cav2.1 and Cav2.3 ...... via GABAB receptor activation
@en
Differential Cav2.1 and Cav2.3 ...... via GABAB receptor activation.
@nl
P2860
P50
P356
P1476
Differential Cav2.1 and Cav2.3 ...... via GABAB receptor activation
@en
P2093
Géza Berecki
P2860
P304
P356
10.1085/JGP.201311104
P577
2014-04-01T00:00:00Z